

#### HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

## Health Partners Plans

## Iron Chelating Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business:   Medicaid  CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
Diagnosis Code:	Diagnosis:			
HPP's maximum approval time is 12 months but may be less depending on the drug.				

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.			
Q1. Is this a request for initiation of th [If no, skip to question 10.]	erapy with the requested drug?		
☐ Yes	□ No		
	for a diagnosis that is indicated in the United States Food and Drug age labeling or a medically accepted indication?		
☐ Yes	□ No		
	the requested drug according to Food and Drug Administration (FDA)-approved ed compendia or peer-reviewed medical literature?		
🗌 Yes	□ No		
	ation of therapy consistent with Food and Drug Administration (FDA)-approved ed compendia or peer-reviewed medical literature?		
☐ Yes	□ No		
Q5. Is the requested drug prescribed	by or in consultation with a specialist (i.e. hematologist)?		
🗌 Yes	□ No		
Q6. Does the patient have a history o	f a contraindication to the requested drug?		
🗌 Yes	□ No		
Q7. Has baseline lab testing been do package labeling? Note: Please attac	ne as recommended in the Food and Drug Administration (FDA)-approved the documentation.		
This telecopy transmission contains confidential informa	tion belonging to the sender that is legally privileged. This information is intended only for the use of the individual or		

entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



#### HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

## Health Partners Plans

# Iron Chelating Agents

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
Yes	□ No		
Q8. Is this a request for a non-preferred iron	ר chelating agent?		
Yes	□ No		
	rapeutic failure with or contraindication or intolerance to the preferred iron eptable for the diagnosis? Note: Please attach documentation.		
Yes	□ No		
Q10. Has the patient demonstrated tolerabil attach documentation.	lity and a positive clinical response to the requested drug? Note: Please		
Yes	□ No		
Q11. Is the requested drug prescribed by or	r in consultation with a specialist (i.e. hematologist)?		
Yes	□ No		
	of therapy consistent with Food and Drug Administration (FDA)-approved npendia or peer-reviewed medical literature?		
☐ Yes	□ No		
Q13. Has the patient received recent lab mo approved package labeling? Note: Please a	onitoring as recommended in the Food and Drug Administration (FDA)-		
☐ Yes	□ No		
Q14. Is continuing treatment with the request Food and Drug Administration (FDA)-approx	sted drug indicated based on recent lab results as recommended in the ved package labeling?		
☐ Yes	□ No		
Q15. Additional Information:			

Prescriber Signature

Date

Updated for 2023

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document